Bank of New York Mellon
INZY

Bank of New York Mellon’s Inozyme Pharma INZY Stock Holding History

Bank of New York Mellon’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-155,695
Closed -$142K – 4203
2025
Q1 		$142K Hold
155,695
– – ﹤0.01% 3958
2024
Q4 		$431K Sell
155,695
-1
-0% -$4 ﹤0.01% 3600
2024
Q3 		$814K Sell
155,696
-35,200
-18% -$183K ﹤0.01% 3257
2024
Q2 		$851K Buy
190,896
+26,464
+16% +$128K ﹤0.01% 3288
2024
Q1 		$1.26M Buy
164,432
+6,417
+4% +$35.2K ﹤0.01% 3026
2023
Q4 		$673K Buy
158,015
+16,874
+12% +$59.9K ﹤0.01% 3392
2023
Q3 		$593K Sell
141,141
-563
-0.4% -$2.86K ﹤0.01% 3455
2023
Q2 		$789K Buy
141,704
+94,539
+200% +$559K ﹤0.01% 3341
2023
Q1 		$270K Buy
47,165
+26,922
+133% +$71.1K ﹤0.01% 3789
2022
Q4 		$21.3K Hold
20,243
– – ﹤0.01% 4347
2022
Q3 		$54K Sell
20,243
-1,655
-8% -$5.99K ﹤0.01% 4307
2022
Q2 		$105K Sell
21,898
-18,115
-45% -$78.8K ﹤0.01% 4216
2022
Q1 		$164K Sell
40,013
-1,183
-3% -$6.96K ﹤0.01% 4299
2021
Q4 		$281K Buy
41,196
+778
+2% +$6.72K ﹤0.01% 4126
2021
Q3 		$469K Buy
40,418
+3,872
+11% +$60.4K ﹤0.01% 3849
2021
Q2 		$623K Buy
36,546
+13,209
+57% +$230K ﹤0.01% 3667
2021
Q1 		$462K Buy
23,337
+1,988
+9% +$43.9K ﹤0.01% 3731
2020
Q4 		$440K Buy
21,349
+1,964
+10% +$46.8K ﹤0.01% 3679
2020
Q3 		$509K Buy
+19,385
New +$481K ﹤0.01% 3486

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Bank of New York Mellon's INZY Position: Q2 2025 in Review

Bank of New York Mellon sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 155,695 shares — an estimated $142K sold.

Bank of New York Mellon first reported a position in INZY in Q3 2020 and held it in 19 quarters. The position peaked at $1.26M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Bank of New York Mellon reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 155,695 Inozyme Pharma shares in Q2 2025, an estimated $142K.
  • Bank of New York Mellon first reported a position in Inozyme Pharma in Q3 2020 and held it in 19 quarters.
  • Bank of New York Mellon's Inozyme Pharma position peaked at $1.26M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.